Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: liver disease + liver diseases + solagran  Related to the article below (Last Update: 5/5/2008)

Save your liver from Hepatitis B
Health24.com, South Africa -
Imagine a disease far more contagious than HIV, that doesn't go away, that can cause liver cancer and that your child can easily pick up from an infected ...
Can-Fite Successfully Completed Phase I Clinical Trial with its 2 ...
Business Wire (press release), CA -
Can-Fite currently intends to develop CF102 for the treatment of liver diseases including HCC and HCV. CF102, which was developed based on Can-Fite's ...
MIT Tech Review Talks to Systems Biologist Leroy Hood
Medgadget.com, CA -
These blood fingerprints, then, are not assays for a disease; they're assays for all disease. We've looked at two organ systems: the brain and the liver. ...
Liver Diseases: A Huge European Health Burden, But Some Trends are ...
FOXBusiness - Apr 23, 2008
Hepatologists (liver disease specialists) study and treat a variety of acute and chronic conditions affecting this largest internal organ of the body. ...
Bile Duct Congestion Can Lead to Intestinal Diseases and Liver ...
Natural News.com, AZ - May 2, 2008
Gallbladder disease generally originates in the liver. When the occurrence of gallstones in the bile ducts of the liver, and, eventually the development of ...
Panel to revisit 'chronic Lyme disease' guidelines
Newsday, NY - May 3, 2008
Poretz told Newsday antibiotic overuse can lead to liver, kidney and bone marrow toxicity. "Antibiotics are one of the greatest discoveries of mankind but ...
Awareness--a key to liver wellness
McMurray Almanac, PA - Apr 30, 2008
The program will focus on liver diseases affecting infants, children and adolescents. Leading pediatric liver doctors from Children's Hospital of Pittsburgh ...
Crohn's Disease Treated With Diet and Medication
RedOrbit, TX - May 4, 2008
However, the disease is not always limited to the GI tract; it can also affect the joints, eyes, moods, skin, and liver. Fatigue is another common complaint ...
Liver walk, run is at Mill Lake
Abbotsford Times, Canada - Apr 28, 2008
Since 1969, the Canadian Liver Foundation's mandate has been to reduce the incidence and impact of all liver diseases by providing support for research and ...
NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease
FOXBusiness - Apr 24, 2008
The European Association for the Study of the Liver (EASL) aims to promote investigation into liver disease and improve the treatments that currently exist ...
Source: Google News

DRUG-INDUCED LIVER DISEASE -
HJ Zimmerman - Clinics in Liver Disease, 2000 - Elsevier
... Clear all fields. Clinics in Liver Disease Volume 4, Issue 1, 1 February
2000, Pages 73-96, ... Inc. DRUG-INDUCED LIVER DISEASE. Hyman J ...

Non-alcoholic fatty liver disease -
P ANGULO, KD LINDOR - Journal of Gastroenterology and Hepatology, 2002 - Blackwell Synergy
... Non-alcoholic fatty liver disease. PAUL ANGULO AND KEITH D LINDOR. Abstract. ...
Pharmacological therapy aimed at the underlying liver disease holds promise. ...

A model to predict survival in patients with end-stage liver disease -
P Kamath? - Hepatology, 2001 - doi.wiley.com
Page 1. Special Article A Model to Predict Survival in Patients With End-Stage Liver
Disease ... Page 3. Ambulatory Patients With Noncholestatic Liver Disease. Be- ...

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. -
CA Matteoni, ZM Younossi, T Gramlich, N Boparai, … - Gastroenterology, 1999 - ncbi.nlm.nih.gov
Gastroenterology. 1999 Jun;116(6):1413-9. Click here to read Nonalcoholic fatty
liver disease: a spectrum of clinical and pathological severity. ...

… mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease … -
JJ Smit, AH Schinkel, RP Oude Elferink, AK Groen, … - Cell, 1993 - ncbi.nlm.nih.gov
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete
absence of phospholipid from bile and to liver disease. ...

Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome -
G Marchesini, M Brizi, G Bianchi, S Tomassetti, E … - Diabetes, 2001 - Am Diabetes Assoc
... Nonalcoholic Fatty Liver Disease. ... Metab. Home page KM Utzschneider and SE Kahn The
Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. ...

Association of nonalcoholic fatty liver disease with insulin resistance -
G Marchesini, M Brizi, AM Morselli-Labate, G … - Am J Med, 1999 - Mass Med Soc
... Nonalcoholic Fatty Liver Disease and Insulin Resistance in Nondiabetics. ... Association
of nonalcoholic fatty liver disease with insulin resistance. ...

Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease -
H Tsukuma, T Hiyama, S Tanaka, M Nakao, T Yabuuchi … - New England Journal of Medicine, 1993 - content.nejm.org
Volume 328:1797-1801, June 24, 1993, Number 25. Next Next. Risk Factors for
Hepatocellular Carcinoma among Patients with Chronic Liver Disease. ...

Routes of Infection, Viremia, and Liver Disease in Blood Donors Found to Have Hepatitis C Virus … -
C Conry-Cantilena, M VanRaden, J Gibble, J … - New England Journal of Medicine, 1996 - content.nejm.org
... 26. Next Next. Routes of Infection, Viremia, and Liver Disease in Blood Donors
Found to Have Hepatitis C Virus Infection. Cathy Conry ...

Nonalcoholic fatty liver disease -
JM Clark, FL Brancati, AM Diehl - Gastroenterology, 2002 - Elsevier
GASTROENTEROLOGY 2002;122:1649-1657 Nonalcoholic Fatty Liver Disease ... Liver biopsy
is the most sensitive test for detecting and staging fatty liver disease. ...

Source: Google Scholar

Treating Chronic Liver Diseases - Australia's Solagran Registers New Pharmaceutical In Russia
Australian Biotech Solagran Limited (ASX: SLA) announced that it had received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both its substance Bioeffective® R and the associated medicine Ropren has been finalised. Ropren is a safe and effective natural hepatoprotector which will be used to treat chronic liver disease, including hepatitis and cirrhosis.

Solagran will now focus on scaling up production facilities sufficient to meet the expected demand in Russia. It can also now initiate the next stage of its Ropren strategy which is to obtain pharmaceutical registration in the European Union as a precursor to taking it to North America and Asia.
Ropren is a unique natural medicine. Its active ingredient Bioeffective® R is one of a family of 17 Bioeffectives® that Solagran's research team has developed over ! 30 years. Each has multifaceted activity and few if any side e! ffects.
Ropren has been approved in Russia as a strong and effective natural hepatoprotector. Clinical trials have also demonstrated that Ropren has the potential to normalise lipid metabolism, strengthen the immune system, prevent and treat neurodegenerative disorders, and deal with conditions associated with drug and alcohol addiction.

The ability of Ropren to deal so effectively with chronic liver disease will have a very positive social impact in Russia. There are more than 10 million people with liver disease in Russia and the CIS countries, with up to 1 million new cases and 100,000 deaths each year.

Solagran expects demand for Ropren to treat liver disease alone will reach 320,000 courses in 2010 and exceed 1 million courses per year by 2012.

Initially, the market is expected to be supply constrained, with Solagran only having capacity to meet the demand expected from hospitals and pharmacies in the cities of Moscow and St Pe! tersburg.

The next step for Solagran is to obtain a manufacturing licence which will apply throughout Russia. This process involves obtaining approval firstly at local level, followed by state and finally federal level approval. It is a procedure that usually takes 2-3 months.

Solagran is already well advanced with the expansion of the SibEX plant in Tomsk into a facility capable of producing 20kg of Bioeffective® R per month by November 2007. This will translate into 60,000 courses of Ropren per year. Planning is also progressing in relation to the development of a new plant on SibEX land adjacent to the existing facility that will be capable of producing 100-200kg per month or 300-600,000 courses per year.

At least three additional production facilities are now planned for Russia to produce Bioeffective® A, Bioeffective® V and Bioeffective® R.

Beyond that, Solagran is looking to establish sites in Finland and in Nort! h America (potentially in either British Columbia or the Pacif! ic North west).
An Executive Director has been appointed with primary responsibility for overseeing Solagran's global manufacturing capability.

Solagran's current strategy involves firstly building a strong market position in Russia with Ropren and Bioeffective® A, and then using Russia as a base to take Ropren and other Bioeffectives® to the world.

Chronic liver disease is a significant global problem. In the US, there are some 200,000 new cases, 300,000 hospitalisations and 30,000 deaths each year. Nevertheless, Solagran expects Ropren's very real potential to prevent and treat neurodegenerative disorders (including Alzheimer's and Parkinson's diseases), together with its ability to normalise cholesterol levels, will have a particularly significant impact in that country over time.

While the intention is to obtain registration for Ropren in the European Union prior to pursuing FDA registration in the US, there is a possibility that b! oth could be done in parallel. Enquiries have already been received from a considerable number of individual patients and their families in Europe and the US in relation to the availability of Ropren to treat both liver disease and neurodegenerative disorders.

At the same time, trials in St Petersburg are progressing well with both the injectable and liposomal forms of Bioeffective® R, as well as with Bioeffectives® A, B and N.

Solagran's Directors consider the registration of Bioeffective® R and Ropren to be by far the most significant milestone achieved by Solagran since it listed in 2003. Achieving full registration for a new and multi-faceted pharmaceutical substance of natural origin in less than four years is truly outstanding - particularly given the amount of change that was occurring within the Russian Ministry of Health during the time that Solagran's application was being processed. Normally, the approval process would take at least tw! ice as long.

Shortcutting this process was only ! possible due to the outstanding efficacy and safety of Ropren, the stature and reputation of Solagran's Executive Chairman Dr Vagif Soultanov within the Russian medical research community, the professionalism and dedication shown by Solagran's project team in Russia led by Professor Victor Roshchin.

Registration opens the door for Solagran to begin to activate its global development strategy. When executed successfully, that strategy has the potential to create a whole new direction in medicine involving the use of highly effective but low side-effect natural Bioeffectives®.

About Solagran Limited

Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology! enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity.

http://www.solagran.com
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.